Pfizer Lifts 2025 Profit Forecast After Q2 Earnings Beat Sales Hit $14.65 Billion Shares Jump 2.8 Percent

Pfizer has raised its full-year profit outlook after a strong second quarter, driven by robust demand for its blockbuster heart drug Vyndaqel and the blood thinner Eliquis. The company now expects adjusted earnings per share for 2025 to fall between $2.90 and $3.10, up from its earlier range of $2.80 to $3.00.

Second-quarter revenue soared to $14.65 billion, easily surpassing analyst expectations of $13.56 billion, helped by a $22 million boost from favorable foreign exchange rates. Vyndaqel and Vyndamax sales came in at $1.62 billion, slightly beating forecasts, while Eliquis revenue hit $2 billion, outpacing analyst estimates.

Pfizer’s adjusted earnings reached 78 cents per share in Q2—well above the 58 cents predicted by analysts. The company’s shares climbed 2.8% in premarket trading to $24.19 after the announcement.

Despite ongoing pressure from the Trump administration to lower drug prices and looming 15% tariffs on imports from the EU, Pfizer stated it has sufficient manufacturing capacity at its 10 U.S. sites to avoid major disruption, and is prepared to shift production if necessary. Investors are also watching for policy changes under RFK Jr., as vaccines make up about 20% of Pfizer’s revenue.

The updated forecast includes a one-time 20 cent per share charge related to a recent licensing deal with China’s 3SBio for an experimental cancer therapy.

With quarterly results outpacing Wall Street’s expectations, Pfizer is signaling confidence as it navigates a challenging regulatory and economic landscape.